Vaderis Therapeutics
Business Services · Switzerland · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Lichtstrasse 35, Basel, Basel-City, 4056...Phone Number
(844) 823-3747Website
www.vaderis.comRevenue
$5.1 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Vaderis Therapeutics
Vaderis Therapeutics AG is a privately held clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, focused on developing targeted therapies for rare vascular diseases. The company was established with the objective of addressing serious medical conditions for which patients have limited or no approved treatment options. Its research strategy centers on understanding the biological mechanisms underlying vascular disorders and developing medicines intended to address disease processes rather than simply managing individual symptoms.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Vaderis Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Vaderis Therapeutics
Check if Vaderis Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Vaderis Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Vaderis Therapeutics had a recent Job posting/layoffs
Check out if Vaderis Therapeutics is spiking on competitors!
Earning: See what the market has to say on Vaderis Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Vaderis Therapeutics has new funding data
Product Launch: Get notified when Vaderis Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Vaderis Therapeutics financials insights
Gather financial insights about Vaderis Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2026
Series B
$152M
Vaderis Therapeutics Tech Stack
A closer look at the technologies used by Vaderis Therapeutics
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Azmi Nabulsi has recently joined the organization as Chief Executive Officer & President. Previously, Nabulsi served as Chief Operating Officer for Phathom Pharmaceuticals.
Executive Moves, New Hire
New Hire
Executive Move
Vaderis has announced that Azmi Nabulsi has joined the organization as Chief Executive Officer & President.
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company
Vaderis Therapeutics News & Media
EQT Life Sciences participates in Vaderis Therapeutics' USD 152 million Series B financing
STOCKHOLM, Aug. 11, 2026 /PRNewswire/ -- EQT Life Sciences is investing USD 17.5 million in Vaderis Therapeutics as part of the Swiss company's USD 152 million Series B financing The financing will support the initiation of the global Phase 3 HEROIC study evaluating engasertib, a...Vaderis Therapeutics AG | - WebDisclosure
Vaderis Therapeutics closes $152 million Series B financing and starts global Phase 3 HEROIC study of engasertib for Hereditary Hemorrhagic Telangiectasia, marking a significant advancement in developing a therapy for the rare vascular diseaseVaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia Provides the...Vaderis Therapeutics Announces Oversubscribed $152 Million Series B Financing and Initiation of the Global Phase 3 HEROIC Study of Engasertib for Hereditary Hemorrhagic Telangiectasia
$152 million Series B financing by private placement to select investors, co-led by Life Sciences at Goldman Sachs Alternatives and TCGX, with participation from Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, and existing investors Medicxi and Droia Provides the...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Vaderis Therapeutics
Sign Up For FreeTo access detailed company insights
Vaderis Therapeutics AG is a privately held clinical-stage biopharmaceutical company headquartered in Basel, Switzerland, focused on developing targeted therapies for rare vascular diseases. The company was established with the objective of addressing serious medical conditions for which patients have limited or no approved treatment options. Its r... Read More
